ArticleMicroorganisms2025
Early Diagnosis and Monitoring of Adaptive Immune Response in a Cohort of Mild Mpox Patients During the 2022 Wave.
Article in Microorganisms, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Mpox in Europe, 2022-2026: A Scoping Review of Viral Clades, Host Determinants of Severity and Antiviral Therapy.Viruses · 2026Article
- Genomic, virologic, and epidemiologic surveillance to track intrafamilial Mpox, Brazil.Microbiology spectrum · 2026Article
- A bioinformatic analysis to systematically unveil shared pathways and molecular mechanisms underlying monkeypox and its predominant neurological manifestations.Frontiers in cellular and infection microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Our study wanted to describe the kinetics of serological and adaptive immune responses in mpox patients.
methodsFourteen patients with laboratory-confirmed mpox were tested at different time points after the symptom onset. An immunofluorescence assay was performed to evaluate the seroconversion kinetics of specific IgA, IgM, and IgG. Moreover, the characterization of the adaptive immunological profile of T- and B-cells was performed.
resultsThe antibody kinetics revealed the faster and more effective seroconversion of specific IgA than IgM. Moreover, we detected an increase in Active memory B cells and CD8+ cells in the early phases of infection, and a reduction in CD4+ T-cells in the mpox patients with respect to the controls and found the presence of higher levels of Treg cells in the HIV+ patients in the early phase of infection.
conclusionOur data highlight the relevance of specific IgA testing early after the symptom onset, suggesting a possible role as a marker in early diagnosis, especially in close contact subjects. Furthermore, the different maturation states of effector cells in HIV+ patients, together with high Treg levels, may lead us to better understand the role of MPXV-HIV co-infection and identify potential cellular markers to monitor the excessive immune activation involved in mpox disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.